Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Giulia, Siravegna"'
Autor:
Giovanni Crisafulli, Giulia Siravegna
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/680136e88aff44b999c21f9107ae225a
Autor:
Jun Tian, Jonathan H. Chen, Sherry X. Chao, Karin Pelka, Marios Giannakis, Julian Hess, Kelly Burke, Vjola Jorgji, Princy Sindurakar, Jonathan Braverman, Arnav Mehta, Tomonori Oka, Mei Huang, David Lieb, Maxwell Spurrell, Jill N. Allen, Thomas A. Abrams, Jeffrey W. Clark, Andrea C. Enzinger, Peter C. Enzinger, Samuel J. Klempner, Nadine J. McCleary, Jeffrey A. Meyerhardt, David P. Ryan, Matthew B. Yurgelun, Katie Kanter, Emily E. Van Seventer, Islam Baiev, Gary Chi, Joy Jarnagin, William B. Bradford, Edmond Wong, Alexa G. Michel, Isobel J. Fetter, Giulia Siravegna, Angelo J. Gemma, Arlene Sharpe, Shadmehr Demehri, Rebecca Leary, Catarina D. Campbell, Omer Yilmaz, Gad A. Getz, Aparna R. Parikh, Nir Hacohen, Ryan B. Corcoran
Publikováno v:
Nature Medicine. 29:458-466
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augm
Autor:
Federica Morano, Filippo Pietrantonio, Giovanni Crisafulli, Benedetta Mussolin, Andrea Cassingena, Monica Montone, Alice Bartolini, Ludovic Barault, Antonia Martinetti, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Silvia Marsoni, Alberto Bardelli, Giulia Siravegna
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Background The analysis of circulating free tumour DNA (ctDNA) in blood, commonly referred as liquid biopsy, is being used to characterise patients with solid cancers. Tumour-specific genetic variants can also be present in DNA isolated from other bo
Externí odkaz:
https://doaj.org/article/31f720781e08479a8d6c55bca6f78276
Autor:
Beth O. Van Emburgh, Sabrina Arena, Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Giorgio Corti, Benedetta Mussolin, Federica Baldi, Michela Buscarino, Alice Bartolini, Emanuele Valtorta, Joana Vidal, Beatriz Bellosillo, Giovanni Germano, Filippo Pietrantonio, Agostino Ponzetti, Joan Albanell, Salvatore Siena, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Clara Montagut, Alberto Bardelli
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-9 (2016)
Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those
Externí odkaz:
https://doaj.org/article/24cf071741ce4d09aa89b3a6aab76cd5
Autor:
Andrew X. Zhu, Nabeel Bardeesy, Ryan B. Corcoran, Dejan Juric, Alberto Bardelli, Ralph Tiedt, Diana Graus Porta, Gad Getz, A. John Iafrate, James R. Stone, David P. Ryan, Pascal Furet, Christelle Stamm, Louise Barys, Barbara Schacher-Engstler, Sabrina Baltschukat, Joseph M. Gurski, Emily E. Van Seventer, Jiaoyuan Elisabeth Sun, Laura Henderson, Stephanie Reyes, Benedetta Mussolin, Avinash Kambadakone, Vikram Deshpande, Phuong Vu, Jochen K. Lennerz, Leanne G. Ahronian, Ignaty Leshchiner, Giulia Siravegna, Leah Y. Liu, Supriya K. Saha, Lipika Goyal
Complete Data for Genetic Analysis of ctDNA and Tumor Tissue for All Samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::259d7240a0c496326f717ca14ca60e36
https://doi.org/10.1158/2159-8290.22531277.v1
https://doi.org/10.1158/2159-8290.22531277.v1
Autor:
Ryan B. Corcoran, Theodore S. Hong, Alberto Bardelli, A. John Iafrate, Jochen K. Lennerz, David P. Ryan, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Nicholas A. Jessop, Jason T. Godfrey, Darrell R. Borger, Benedetta Mussolin, Giulia Siravegna, Leanne G. Ahronian, Eunice L. Kwak
Supplementary Figure S1. Absence of ALK or ROS1 rearrangements in Patient #3. Supplementary Figure S2. CT images for Patient #5. Supplementary Figure S3. Interlesional heterogeneity in a HER2-amplified EGC patient. Supplementary Table S1. 40 gene cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c25688491b68e9bba0589ab1bbe77ed
https://doi.org/10.1158/2159-8290.22531379.v1
https://doi.org/10.1158/2159-8290.22531379.v1
Autor:
Salvatore Siena, Silvia Giordano, Federica Di Nicolantonio, Livio Trusolino, Paolo Comoglio, Victor E. Velculescu, Mark Sausen, Luis A. Diaz, Marcello Gambacorta, Alessio Amatu, Giorgio Corti, Silvio Veronese, Timothy Perera, Carlo Zanon, Calogero Lauricella, Francesco Galimi, Giorgia Migliardi, Maria Apicella, Davide Zecchin, Andrea Cassingena, Elisa Scala, Andrea Sartore-Bianchi, Giulia Siravegna, Emanuele Valtorta, Sebastijan Hobor, Andrea Bertotti, Simona Corso, Alberto Bardelli
Supplementary Figure S4 - PDF file 19K, Ectopic expression of MET in cetuximab sensitive DIFI and LIM1215 cell lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e3c15de8cb9ba777bef634b043bc13
https://doi.org/10.1158/2159-8290.22529322.v1
https://doi.org/10.1158/2159-8290.22529322.v1
Autor:
Ryan B. Corcoran, Rebecca S. Heist, Aaron N. Hata, Liron Bar-Peled, Giulia Siravegna, Jochen K. Lennerz, Samuel J. Klempner, Justin F. Gainor, Dejan Juric, Islam Baiev, Mustafa Sakhi, Katerina A. Fella, Mohammed U. Syed, Alexa G. Michel, Lesli A. Kiedrowski, Junbing Zhang, Meagan B. Ryan, Chendi Li, Jessica J. Lin, Noritaka Tanaka
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6aa2acd4b997a9e54783ae8dd826d4
https://doi.org/10.1158/2159-8290.c.6549266
https://doi.org/10.1158/2159-8290.c.6549266
Autor:
Brian M. Wolpin, Nabeel Bardeesy, Vincent Zoete, Antoine Daina, Matthew Meyerson, Ryan B. Corcoran, Andrew D. Cherniack, William C. Hahn, Pasi A. Jänne, Deborah Schrag, Kimmie Ng, Claudio Zanna, Anna Pokorska-Bocci, Geoffrey I. Shapiro, Emma R. Hill, Sarah Denning, Rachel B. Keller, Ryan J. Sullivan, Anne Vaslin Chessex, Franck Brichory, Anuj K. Patel, Jiping Wang, Thomas E. Clancy, Thomas A. Abrams, Atul B. Shinagare, Maureen Loftus, Lauren K. Brais, Lei Shi, Lipika Goyal, Giulia Siravegna, Jonathan A. Nowak, Jason L. Hornick, Isobel J. Fetter, Douglas A. Rubinson, Hersh V. Gupta, Liam F. Spurr, Yvonne Y. Li, Qibiao Wu, Srivatsan Raghavan, James M. Cleary
Supplemental Tables and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1463328c4adeb3363ae5c305a7b511bc
https://doi.org/10.1158/2159-8290.22539857
https://doi.org/10.1158/2159-8290.22539857
Autor:
Alberto Bardelli, Salvatore Siena, Gang Li, Andrea Sartore Bianchi, Federica Di Nicolantonio, Robert Wild, Robert Shoemaker, Shunqi Yan, Roopal Patel, Nicholas Cam, Alice Bartolini, Benedetta Mussolin, Luca Novara, Giuseppe Rospo, Giorgio Corti, Luca Lazzari, Giovanni Crisafulli, Giulia Siravegna, Ge Wei, Sandra Misale, Mariangela Russo
Supplementary Figure S1. LMNA-NTRK1 genetic rearrangement detected in patient's plasma and xeno. Supplementary Figure S2. Acquisition of mutations in the TRKA kinase domain drives secondary resistance to entrectinib in Ba/F3 TRKA WT cells. Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057302585d4404e254351678a966601f
https://doi.org/10.1158/2159-8290.22531250.v1
https://doi.org/10.1158/2159-8290.22531250.v1